Antengene Corporation Ltd
HKEX:6996

Watchlist Manager
Antengene Corporation Ltd Logo
Antengene Corporation Ltd
HKEX:6996
Watchlist
Price: 3.25 HKD -7.67% Market Closed
Market Cap: 2.2B HKD

Antengene Corporation Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Antengene Corporation Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Antengene Corporation Ltd
HKEX:6996
Total Current Assets
ÂĄ956.2m
CAGR 3-Years
-27%
CAGR 5-Years
5%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Current Assets
ÂĄ27.4B
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Current Assets
ÂĄ15.8B
CAGR 3-Years
16%
CAGR 5-Years
18%
CAGR 10-Years
22%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Current Assets
ÂĄ34.8B
CAGR 3-Years
5%
CAGR 5-Years
10%
CAGR 10-Years
18%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Current Assets
ÂĄ37.4B
CAGR 3-Years
-7%
CAGR 5-Years
-2%
CAGR 10-Years
12%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Total Current Assets
ÂĄ2.4B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
N/A

Antengene Corporation Ltd
Glance View

Market Cap
2.2B HKD
Industry
Pharmaceuticals

Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.

Intrinsic Value
0.42 HKD
Overvaluation 87%
Intrinsic Value
Price

See Also

What is Antengene Corporation Ltd's Total Current Assets?
Total Current Assets
956.2m CNY

Based on the financial report for Dec 31, 2024, Antengene Corporation Ltd's Total Current Assets amounts to 956.2m CNY.

What is Antengene Corporation Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
5%

Over the last year, the Total Current Assets growth was -23%. The average annual Total Current Assets growth rates for Antengene Corporation Ltd have been -27% over the past three years , 5% over the past five years .

Back to Top